Investigational Ms Drug Evobrutinib Has Potential Study Shows
Evobrutinib is the first BTK inhibitor to be evaluated for the treatment of MS, although other drugs in the class have been used to treat certain forms of cancer. It’s currently undergoing clinical trials for safety and efficacy, and new results from a phase 2 study were presented on April 18 during the 2021 annual meeting of the American Academy of Neurology (AAN). Earlier results of the study were published in 2019 in the New England Journal of Medicine....